Metabostemness: A new cancer hallmark

Frontiers in Oncology

Volumn 4, Issue SEP, 2014, Pages

  Menendez, Javier A ^a,b   Alarco´n, Toma´s ^c  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^c CENTRE DE RECERCA MATEMÀTICA   (Spain)

Author keywords

Cancer stem cells; Epigenetic landscapes; Metabolism; Oncometabolites; Reprogramming; Stemness; Waddington

Indexed keywords

BIGUANIDE DERIVATIVE; SIRTUIN;

AGING; ARTICLE; CARCINOGENESIS; CELL DEDIFFERENTIATION; CELL DIFFERENTIATION; CELL FATE; CELL RENEWAL; CLINICAL TRIAL (TOPIC); DNA MODIFICATION; DRUG TARGETING; EPIGENETICS; GERONCOGENESIS; HUMAN; HYPOTHESIS; MASS SPECTROMETRY; METABOLIC DISORDER; METABOLIC FLUX ANALYSIS; METABOLOMICS; METABOSTEMNESS; MUTATION; NEOPLASM; NUTRIGENOMICS; PHENOME; PHENOTYPE; PLURIPOTENT STEM CELL; STEMNESS;

EID: 84907022547     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00262     Document Type: Article

References (208)

1. Adam, J., Yang, M., Soga, T., and Pollard, P. J. (2014). Rare insights into cancer biology. Oncogene 33, 2547-56.
2. Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S. J., and Clarke, M. F. (2003). Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U S A 100, 3983-8.
3. Armond, J. W., Saha, K., Rana, A. A., Oates, C. J., Jaenisch, R., Nicodemi, M., and Mukherjee, S. (2014). A stochastic model dissects cell states in biological transition processes. Sci. Rep. 4, 3692.
4. Bednar, F., and Simeone, D. M. (2012). Metformin and cancer stem cells: old drug, new targets. Cancer Prev. Res. (Phila). 5, 351-4.
5. Belenky, P., Bogan, K. L., and Brenner, C. (2007). NAD+ metabolism in health and disease. Trends Biochem. Sci. 32, 12-9.
6. Beltran, A. S., Rivenbark, A. G., Richardson, B. T., Yuan, X., Quian, H., Hunt, J. P., et al. (2011). Generation of tumor-initiating cells by exogenous delivery of OCT4 transcription factor. Breast Cancer Res. 13, R94.
7. Ben-Porath, I., Thomson, M. W., Carey, V. J., Ge, R., Bell, G. W., Regev, A., et al. (2008). An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 40, 499-507.
8. Bensaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N., Nakano, K., Bartrons, R., et al. (2006). TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126, 107-20.
9. Berkers, C. R., Maddocks, O. D., Cheung, E. C., Mor, I., and Vousden, K. H. (2013). Metabolic regulation by p53 family members. Cell Metab. 18, 617-33.
10. Bond, J. A., Oddweig Ness, G., Rowson, J., Ivan, M., White, D., and Wynford-Thomas, D. (1996). Spontaneous de-differentiation correlates with extended lifespan in transformed thyroid epithelial cells: an epigenetic mechanism of tumour progression? Int. J. Cancer 67, 563-72.
11. Bonnet, D., and Dick, J. E. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730-7.
12. Bonuccelli, G., Tsirigos, A., Whitaker-Menezes, D., Pavlides, S., Pestell, R. G., Chiavarina, B., et al. (2010). Ketones and lactate "fuel" tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle 9, 3506-14.
13. Borger, D. R., Goyal, L., Yau, T., Poon, R. T., Ancukiewicz, M., Deshpande, V., et al. (2014). Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma. Clin. Cancer Res. 20, 1884-90.
14. Boumahdi, S., Driessens, G., Lapouge, G., Rorive, S., Nassar, D., Le Mercier, M., et al. (2014). SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma. Nature 511, 246-50.
15. Bukowiecki, R., Adjaye, J., and Prigione, A. (2014). Mitochondrial function in pluripotent stem cells and cellular reprogramming. Gerontology 60, 174-82.
16. Cairns, R. A., and Mak, T. W. (2013). Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. Cancer Discov. 3, 730-41.
17. Campos-Sa´nchez, E., and Cobaleda, C. (2014). Tumoral reprogramming: Plasticity takes a walk on the wild side. Biochim. Biophys. Acta pii: S1874-9399(14)00191-6. doi: 10.1016/j.bbagrm.2014.07.003.
18. Chaffer, C. L., Brueckmann, I., Scheel, C., Kaestli, A. J., Wiggins, P. A., Rodrigues, L. O., et al. (2011). Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc. Natl. Acad. Sci. U S A 108, 7950-5.
19. Chen, M., Zhang, J., Li, N., Qian, Z., Zhu, M., Li, Q., Zheng, J., et al. (2011). Promoter hypermethylation mediated downregulation of FBP1 in human hepatocellular carcinoma and colon cancer. PLoS One 6, e25564.
20. Chen, T., Shen, L., Yu, J., Wan, H., Guo, A., Chen, J., et al. (2011). Rapamycin and other longevity-promoting compounds enhance the generation of mouse induced pluripotent stem cells. Aging Cell 10, 908-11.
21. Chin, M. H., Mason, M. J., Xie, W., Volinia, S., Singer, M., Peterson, C., et al. (2009). Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell 5, 111-23.
22. Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., et al. (2009). Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-40.
23. Chowdhury, R., Yeoh, K. K., Tian, Y. M., Hillringhaus, L., Bagg, E. A., Rose, N. R., et al. (2011). The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep. 12, 463-9.
24. Ciavardelli, D., Rossi, C., Barcaroli, D., Volpe, S., Consalvo, A., Zucchelli, M., et al. (2014). Breast cancer stem cells rely on fermentative glycolysis and are sensitive to 2-deoxyglucose treatment. Cell Death Dis. 5, e1336.
25. Corominas-Faja, B, Cufi´, S., Oliveras-Ferraros, C., Cuya`s, E., Lo´pez-Bonet, E., Lupu, R., et al. (2013). Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway. Cell Cycle 12, 3109-24.
26. Cufi, S., Corominas-Faja, B., Vazquez-Martin, A., Oliveras-Ferraros, C., Dorca, J., Bosch- Barrera, J., et al. (2012). Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts. Oncotarget 3, 395-8.
27. Cufi´, S., Vazquez-Martin, A., Oliveras-Ferraros, C., Martin-Castillo, B., Joven, J., and Menendez, J. A. (2010). Metformin against TGFß-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. Cell Cycle 9, 4461-8.
28. Cuya`s, E., Corominas-Faja, B., and Menendez, J. A. (2014). The nutritional phenome of EMT induced cancer stem-like cells. Oncotarget 5, 3970-82.
29. Dang, C. V. (2010). Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. Cancer Res. 70, 859-62.
30. Dang, C. V., Le, A., and Gao, P. (2009). MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin. Cancer Res. 15, 6479-83.
31. DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., and Thompson, C. B. (2008). The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 7, 11-20.
32. Del Barco, S., Vazquez-Martin, A., Cufi´, S., Oliveras-Ferraros, C., Bosch-Barrera, J., Joven, J., et al. (2011). Metformin: multi-faceted protection against cancer. Oncotarget 2, 896-917.
33. Dong, C., Yuan, T., Wu, Y., Wang, Y., Fan, T. W., Miriyala, S., et al. (2013). Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell 23, 316-331.
34. Enver, T., Pera, M., Peterson, C., and Andrews, P. W. (2009). Stem cell states, fates, and the rules of attraction. Cell Stem Cell 4, 387-97.
35. Feldman, J. L., Dittenhafer-Reed, K. E., and Denu, J. M. (2012). Sirtuin catalysis and regulation. J. Biol. Chem. 287, 42419-27.
36. Ferguson, L. R., and Schlothauer, R. C. (2012). The potential role of nutritional genomics tools in validating high health foods for cancer control: broccoli as example. Mol. Nutr. Food Res. 56, 126-46.
37. Fessler, E., Dijkgraaf, F. E., De Sousa, E., Melo, F., and Medema, J. P. (2013). Cancer stem cell dynamics in tumor progression and metastasis: is the microenvironment to blame? Cancer Lett. 341, 97-104.
38. Floor, S. L., Dumont, J. E., Maenhaut, C., and Raspe, E. (2012). Hallmarks of cancer: of all cancer cells, all the time? Trends Mol. Med. 18, 509-15.
39. Floor, S., van Staveren, W. C., Larsimont, D., Dumont, J. E., and Maenhaut, C. (2011). Cancer cells in epithelial-to-mesenchymal transition and tumor-propagating-cancer stem cells: distinct, overlapping or same populations. Oncogene 30, 4609-21.
40. Folmes, C. D., Arrell, D. K., Zlatkovic-Lindor, J., Martinez-Fernandez, A., Perez-Terzic, C., Nelson, T. J., and Terzic, A. (2013). Metabolome and metaboproteome remodeling in nuclear reprogramming. Cell Cycle 12, 2355-65.
41. Folmes, C. D., Dzeja, P. P., Nelson, T. J., and Terzic, A. (2012b) Metabolic plasticity in stem cell homeostasis and differentiation. Cell Stem Cell 11, 596-606.
42. Folmes, C. D., Nelson, T. J., and Terzic, A. (2011b). Energy metabolism in nuclear reprogramming. Biomark. Med. 5, 715-29.
43. Folmes, C. D., Nelson, T. J., Dzeja, P. P., and Terzic, A. (2012a). Energy metabolism plasticity enables stemness programs. Ann. N. Y. Acad. Sci. 1254, 82-9.
44. Folmes, C. D., Nelson, T. J., Martinez-Fernandez, A., Arrell, D. K., Lindor, J. Z., Dzeja, P. P., et al. (2011a). Somatic oxidative bioenergetics transitions into pluripotency-dependent glycolysis to facilitate nuclear reprogramming. Cell Metab. 14, 264-71.
45. Frezza, C., Pollard, P. J., and Gottlieb, E. (2011). Inborn and acquired metabolic defects in cancer. J. Mol. Med. (Berl). 89, 213-20.
46. Friedmann-Morvinski, D., and Verma. I. M. (2014). Dedifferentiation and reprogramming: origins of cancer stem cells. EMBO Rep. 15, 244-53.
47. Gaude, E., and Frezza, C. (2014). Defects in mitochondrial metabolism and cancer. Cancer Metab. 2, 10.
48. Godar, S., Ince, T. A., Bell, G. W., Feldser, D., Donaher, J. L., Bergh, J., et al. (2008). Growth inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. Cell 134, 62-73.
49. Goding, C. R., Pei, D., and Lu, X. (2014). Cancer: pathological nuclear reprogramming? Nat. Rev. Cancer 14, 568-73.
50. Goel, A., Mathupala, S. P., and Pedersen, P. L. (2003). Glucose metabolism in cancer. Evidence that demethylation events play a role in activating type II hexokinase gene expression. J. Biol. Chem. 278, 15333-40.
51. Guan, J. L., Simon, A. K., Prescott, M., Menendez, J. A., Liu, F., Wang, F, et al. (2013). Autophagy in stem cells. Autophagy 9, 830-49.
52. Gupta, P. B., Fillmore, C. M., Jiang, G., Shapira, S. D., Tao, K., Kuperwasser, C., et al. (2011). Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 146, 633-44.
53. Hanahan, D., and Weinberg, R. A. (2000). The hallmarks of cancer. Cell 100,57-70.
54. Hanahan, D., and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-74.
55. Hanna, J. H., Saha, K., and Jaenisch, R. (2010). Pluripotency and cellular reprogramming: facts, hypotheses, unresolved issues. Cell 143, 508-25.
56. Hanna, J., Saha, K., Pando, B., van Zon, J., Lengner, C. J., Creyghton, M. P., et al. (2009). Direct cell reprogramming is a stochastic process amenable to acceleration. Nature 462, 595-601.
57. Hassiotou, F., Hepworth, A. R., Beltran, A. S., Mathews, M. M., Stuebe, A. M., Hartmann, P. E., et al. (2013). Expression of the Pluripotency Transcription Factor OCT4 in the Normal and Aberrant Mammary Gland. Front. Oncol. 3, 79.
58. Hernandez-Vargas, H., Sincic, N., Ouzounova, M., and Herceg, Z. (2009). Epigenetic signatures in stem cells and cancer stem cells. Epigenomics 1, 261-80.
59. Hirsch, H. A., Iliopoulos, D., and Struhl, K. (2013). Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc. Natl. Acad. Sci. U S A 110, 972-7.
60. Hirsch, H. A., Iliopoulos, D., Tsichlis, P. N., and Struhl, K. (2009). Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 69, 7507-11.
61. Hitchler, M. J., and Domann, F. E. (2009). Metabolic defects provide a spark for the epigenetic switch in cancer. Free Radic. Biol. Med. 47, 115-27.
62. Hong, H., Takahashi, K., Ichisaka, T., Aoi, T., Kanagawa, O., Nakagawa, M., et al. (2009). Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 460, 1132-5.
63. Hu, J., Locasale, J. W., Bielas, J. H., O'Sullivan, J., Sheahan, K., Cantley, L. C., Vander Heiden, M. G., et al. (2013). Heterogeneity of tumor-induced gene expression changes in the human metabolic network. Nat. Biotechnol. 31, 522-9.
64. Huang J, Sengupta R, Espejo AB, Lee MG, Dorsey JA, Richter M, Opravil S, Shiekhattar R, Bedford MT, Jenuwein T, Berger SL. p53 is regulated by the lysine demethylase LSD1. Nature 449(7158):105-8.
65. Huang, S. (2009). Reprogramming cell fates: reconciling rarity with robustness. Bioessays 31, 546-60.
66. Iliopoulos, D., Hirsch, H. A., and Struhl, K. (2009). An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 139, 693-706.
67. Iliopoulos, D., Hirsch, H. A., and Struhl, K. (2011b). Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res. 71, 3196-201.
68. Iliopoulos, D., Hirsch, H. A., Wang, G., and Struhl, K. (2011a). Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc. Natl. Acad. Sci. U S A 108, 1397-402.
69. Ito, K., and Suda, T. (2014). Metabolic requirements for the maintenance of self-renewing stem cells. Nat. Rev. Mol. Cell Biol. 15, 243-56.
70. Janzer, A., German, N. J., Gonzalez-Herrera, K. N., Asara, J. M., Haigis, M. C., and Struhl, K. (2014). Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells. Proc. Natl. Acad. Sci. U S A 111, 10574-9.
71. Johnson, C., Warmoes, M. O., Shen, X., and Locasale, J. W. (2013). Epigenetics and cancer metabolism. Cancer Lett. pii: S0304-3835(13)00715-5. doi: 10.1016/j.canlet.2013.09.043. [Epub ahead of print]
72. Jones, R. G., and Thompson, C. B. (2009). Tumor suppressors and cell metabolism: A recipe for cancer growth. Genes Dev. 23, 537-48.
73. Jung, J. W., Park, S. B., Lee, S. J., Seo, M. S., Trosko, J. E., and Kang, K. S. (2011). Metformin represses self-renewal of the human breast carcinoma stem cells via inhibition of estrogen receptor-mediated OCT4 expression. PLoS One 6, :e28068.
74. Katada, S., Imhof, A., and Sassone-Corsi, P. (2012). Connecting threads: epigenetics and metabolism. Cell 148, 24-8.
75. Kawamura, T., Suzuki, J., Wang, Y. V., Menendez, S., Morera, L. B., Raya, A., et al. (2009). Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 460, 1140-4.
76. Kawauchi, K., Araki, K., Tobiume, K., and Tanaka, N. (2008). p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat. Cell Biol. 10, 611-8.
77. Kim, S. C., Sprung, R., Chen, Y., Xu, Y., Ball, H., Pei, J., et al. (2006). Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol. Cell 23, 607-18.
78. Kleinsmith, L. J., and Pierce, G. B. Jr. (1964). Multipotentiality of single embryonal carcinoma cells. Cancer Res. 24, 1544-51.
79. Krell, D., Mulholland, P., Frampton, A. E., Krell, J., Stebbing, J., and Bardella, C. (2013). IDH mutations in tumorigenesis and their potential role as novel therapeutic targets. Future Oncol. 9, 1923-35.
80. Kroemer, G., and Pouyssegur, J. (2008). Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13, 472-82.
81. Kung, H. N., Marks, J. R., and Chi, J. T. (2011). Glutamine synthetase is a genetic determinant of cell type-specific glutamine independence in breast epithelia. PLoS Genet 7, e1002229.
82. Leis, O., Eguiara, A., Lopez-Arribillaga, E., Alberdi, M. J., Hernandez-Garcia, S., Elorriaga, K., et al. (2012). Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene 31, 1354-65.
83. Lengerke, C., Fehm, T., Kurth, R., Neubauer, H., Scheble, V., Mu¨ller, F., et al. (2011). Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma. BMC Cancer 11, 42.
84. Levesque, J. P., Winkler, I. G., and Rasko, J. E. (2013). Nichotherapy for stem cells: there goes the neighborhood. Bioessays 35, 183-90.
85. Li, H., Collado, M., Villasante, A., Strati, K., Ortega, S., Cañamero, M., et al. (2009). The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 460, 1136-9.
86. Li, W., Li, K., Wei, W., and Ding, S. (2013). Chemical approaches to stem cell biology and therapeutics. Cell Stem Cell 13, 270-83.
87. Li, X., and Kazgan, N. (2011). Mammalian sirtuins and energy metabolism. Int. J. Biol. Sci. 7, 575-87.
88. Li, Y., Wicha, M. S., Schwartz, S. J., and Sun, D. (2011). Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds. J. Nutr. Biochem. 22, 799-806.
89. Liu, C. G., Lu, Y., Wang, B. B., Zhang, Y. J., Zhang, R. S., Lu, Y., et al. (2011). Clinical implications of stem cell gene Oct-4 expression in breast cancer. Ann. Surg. 253, 1165-71.
90. Liu, C., Cao, X., Zhang, Y., Xu, H., Zhang, R., Wu, Y., et al. (2012). Co-expression of Oct-4 and Nestin in human breast cancers. Mol. Biol. Rep. 39, 5875-81.
91. Liu, C., Kelnar, K., Liu, B., Chen, X., Calhoun-Davis, T., Li, H., et al. (2011). The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat. Med. 17, 211-5.
92. Liu, P. P., Liao, J., Tang, Z. J., Wu, W. J., Yang, J., Zeng, Z. L., et al. (2014). Metabolic regulation of cancer cell side population by glucose through activation of the Akt pathway. Cell Death Differ. 21, 124-35.
93. Liu, X., Wang, X., Zhang, J., Lam, E. K., Shin, V. Y., Cheng, A. S., et al. (2010). effect revisited: an epigenetic link between glycolysis and gastric carcinogenesis. Oncogene 29, 442-50.
94. Locasale, J. W. (2013). Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat. Rev. Cancer 13, 572-83.
95. Lonardo, E., Cioffi, M., Sancho, P., Sanchez-Ripoll, Y., Trabulo, S. M., Dorado, J., et al. (2013). Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells. PLoS One 8, e76518.
96. Lopez-Serra, P., Marcilla, M., Villanueva, A., Ramos-Fernandez, A., Palau, A., Leal, L., et al. (2014). A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect. Nat. Commun. 5, 3608.
97. Lu, C., and Thompson, C. B. (2012). Metabolic regulation of epigenetics. Cell Metab. 16, 9-17.
98. Lundstrom, K. (2013). Past, present and future of nutrigenomics and its influence on drug development. Curr. Drug Discov. Technol. 10, 35-46.
99. MacArthur, B. D., and Lemischka, I. R. (2013). Statistical mechanics of pluripotency. Cell 154, 484-9.
100. Macarthur, B. D., Ma'ayan, A., and Lemischka, I. R. (2009). Systems biology of stem cell fate and cellular reprogramming. Nat. Rev. Mol. Cell Biol. 10, 672-81.
101. Maddocks, O. D., and Vousden, K. H. (2011). Metabolic regulation by p53. J. Mol. Med. (Berl). 89, 237-45.
102. Madison, B. B., Liu, Q., Zhong, X., Hahn, C. M., Lin, N., Emmett, M. J, et al. (2013). LIN28B promotes growth and tumorigenesis of the intestinal epithelium via Let-7. Genes Dev. 27, 2233-45.
103. Maenhaut, C., Dumont, J. E., Roger, P. P., and van Staveren, W. C. (2010). Cancer stem cells: a reality, a myth, a fuzzy concept or a misnomer? An analysis. Carcinogenesis 31, 149-58.
104. Magee, J. A., Piskounova, E., and Morrison, S. J. (2012). Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 21, 283-96.
105. Mahmoudi, S., and Brunet, A. (2012). Aging and reprogramming: a two-way street. Curr. Opin. Cell Biol. 24, 744-56.
106. Mani, S. A., Guo, W., Liao, M. J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., et al. (2008). The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-15.
107. Mario´n, R. M., Strati, K., Li, H., Murga, M., Blanco, R., Ortega, S., et al. (2009). A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 460, 1149-53.
108. Martin-Castillo, B., Vazquez-Martin, A., Oliveras-Ferraros, C., and Menendez, J. A. (2010). Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle 9, 1057-64.
109. Martinez-Outschoorn, U. E., Prisco, M., Ertel, A., Tsirigos, A., Lin, Z., Pavlides, S., et al. (2011). Ketones and lactate increase cancer cell "stemness," driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via Metabolo-Genomics. Cell Cycle 10, 1271-86.
110. Meacham, C. E., and Morrison, S. J. (2013). Tumour heterogeneity and cancer cell plasticity. Nature 501, 328-37.
111. Medema, J. P. (2013). Cancer stem cells: the challenges ahead. Nat. Cell Biol. 15, 338-44.
112. Menendez, J. A., Alarco´n, T., and Joven, J. (2014b). Gerometabolites: the pseudohypoxic aging side of cancer oncometabolites. Cell Cycle 13, 699-709.
113. Menendez, J. A., Alarco´n, T., Corominas-Faja, B., Cuya`s, E., Lo´pez-Bonet, E., Martin, A. G., et al. (2014a). Xenopatients 2.0: reprogramming the epigenetic landscapes of patient-derived cancer genomes. Cell Cycle 13, 358-70.
114. Menendez, J. A., and Joven, J. (2014). Energy metabolism and metabolic sensors in stem cells: the metabostem crossroads of aging and cancer. Adv. Exp. Med. Biol. 824,117-40.
115. Menendez, J. A., and Lupu, R. (2007). Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat. Rev. Cancer 7, 763-77.
116. Menendez, J. A., Joven, J., Aragone`s, G., Barrajo´n-Catala´n, E., Beltra´n-Debo´n, R., Borra´s- Linares, I., et al. (2013b). Xenohormetic and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil: a new family of gerosuppressant agents. Cell Cycle 12, 555-78.
117. Menendez, J. A., Joven, J., Cufi´, S., Corominas-Faja, B., Oliveras-Ferraros, C., Cuya`s, E., et al. (2013a). The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells. Cell Cycle 12, 1166-79.
118. Menendez, J. A., Vellon, L., Oliveras-Ferraros, C., Cufi´, S., and Vazquez-Martin, A. (2011). mTOR-regulated senescence and autophagy during reprogramming of somatic cells to pluripotency: a roadmap from energy metabolism to stem cell renewal and aging. Cell Cycle 10, 3658-77.
119. Meyer, M. J., Fleming, J. M., Lin, A. F., Hussnain, S. A., Ginsburg, E., and Vonderhaar, B. K. (2010). CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor negative breast cancer. Cancer Res. 70, 4624-33.
120. Mihaylova, M. M., Sabatini, D. M., and Yilmaz, O¨. H. (2014). Dietary and metabolic control of stem cell function in physiology and cancer. Cell Stem Cell 14, 292-305.
121. Mohammed, A., Janakiram, N. B., Brewer, M., Ritchie, R. L., Marya, A., Lightfoot, S., et al. (2013). SAntidiabetic Drug Metformin Prevents Progression of Pancreatic Cancer by Targeting in Part Cancer Stem Cells and mTOR Signaling. Transl. Oncol. 6, 649-59.
122. Morris, R., Sancho-Martinez, I., Sharpee, T. O., and Izpisua Belmonte, J. C. (2014). Mathematical approaches to modeling development and reprogramming. Proc. Natl. Acad. Sci. U S A 111, 5076-82.
123. Nishi, M., Sakai, Y., Akutsu, H., Nagashima, Y., Quinn, G., Masui, S., et al. (2014). Induction of cells with cancer stem cell properties from nontumorigenic human mammary epithelial cells by defined reprogramming factors. Oncogene 33, 643-52.
124. Norton, L. (2011). Cancer stem cells, EMT, and seeding: a rose is a rose is a rose? Oncology (Williston Park). 25, 30-2.
125. Oliveras-Ferraros, C., Cufi´, S., Vazquez-Martin, A., Torres-Garcia, V. Z., Del Barco, S., Martin- Castillo, B., et al. (2011). Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: induction of the tumor suppressor miRNA let-7a and suppression of the TGFß-induced oncomiR miRNA-181a. Cell Cycle 10, 1144-51.
126. Pacini, N., and Borziani, F. (2014). Cancer stem cell theory and the warburg effect, two sides of the same coin? Int. J. Mol. Sci. 15, 8893-930.
127. Panopoulos, A. D., Yanes, O., Ruiz, S., Kida, Y. S., Diep, D., Tautenhahn, R., et al. (2012). The metabolome of induced pluripotent stem cells reveals metabolic changes occurring in somatic cell reprogramming. Cell Res. 22, 168-77.
128. Passegue, E., Jamieson, C. H., Ailles, L. E., and Weissman, I. L. (2003). Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proc. Natl. Acad. Sci. U S A 100, 11842-9.
129. Pellerin, L., and Magistretti, P. J. (1994). Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc. Natl. Acad. Sci. U S A 91, 10625-9.
130. Peng, S., Maihle, N. J., and Huang, Y. (2010). Pluripotency factors Lin28 and Oct4 identify a sub population of stem cell-like cells in ovarian cancer. Oncogene 29, 2153-9.
131. Perales-Clemente, E., Folmes, C. D., and Terzic, A. (2014). METABOLIC REGULATION OF REDOX STATUS IN STEM CELLS. Antioxid Redox Signal [Epub ahead of print]
132. Pierce, G. B., and Speers, W. C. (1988). Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation. Cancer Res. 48, 1996-2004.
133. Pollak, M. (2008). Insulin and insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer 8, 915-28.
134. Pollak, M. (2013). Potential applications for biguanides in oncology. J. Clin. Invest. 123, 3693-700.
135. Polytarchou, C., Iliopoulos, D., and Struhl, K. (2012). An integrated transcriptional regulatory circuit that reinforces the breast cancer stem cell state. Proc. Natl. Acad. Sci. U S A 109, 14470-5.
136. Prigione A, Fauler B, Lurz R, Lehrach H, Adjaye J. The senescence-related mitochondrial/oxidative stress pathway is repressed in human induced pluripotent stem cells. Stem Cells (2010) 28(4):721-33.
137. Prigione, A., and Adjaye, J. (2010). Modulation of mitochondrial biogenesis and bioenergetic metabolism upon in vitro and in vivo differentiation of human ES and iPS cells. Int. J. Dev. Biol. 54, 1729-41.
138. Que´net, D., El Ramy, R., Schreiber, V., and Dantzer, F. (2009). The role of poly(ADP ribosyl)ation in epigenetic events. Int. J. Biochem. Cell Biol. 41, 60-5.
139. Quintana, E., Shackleton, M., Foster, H. R., Fullen, D. R., Sabel, M. S., Johnson, T. M., et al. (2010). Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 18, 510-23.
140. Rafalski, V. A., Mancini, E., and Brunet, A. (2012). Energy metabolism and energy-sensing pathways in mammalian embryonic and adult stem cell fate. J. Cell Sci. 125, 5597-608.
141. Rais, Y., Zviran, A., Geula, S., Gafni, O., Chomsky, E., Viukov, S., et al. (2013). Deterministic direct reprogramming of somatic cells to pluripotency. Nature 502, 65-70.
142. Reya, T., Morrison, S. J., Clarke, M. F., and Weissman, I. L. (2001). Stem cells, cancer, and cancer stem cells. Nature 414, 105-11.
143. Riscuta, G., and Dumitrescu, R. G. (2012). Nutrigenomics: implications for breast and colon cancer prevention. Methods Mol. Biol. 863, 343-58.
144. Saha, S. K., Parachoniak, C. A., Ghanta, K. S., Fitamant, J., Ross, K. N., Najem MS, et al. (2014). Mutant IDH inhibits HNF-4a to block hepatocyte differentiation and promote biliary cancer. Nature doi: 10.1038/nature13441. [Epub ahead of print]
145. Salem, A. F., Whitaker-Menezes, D., Lin, Z., Martinez-Outschoorn, U. E., Tanowitz, H. B., Al- Zoubi. M. S., et al. (2012). Two-compartment tumor metabolism: autophagy in the tumor microenvironment and oxidative mitochondrial metabolism (OXPHOS) in cancer cells. Cell Cycle 11, 2545-56.
146. Sarig, R., Rivlin, N., Brosh, R., Bornstein, C., Kamer, I., Ezra, O., et al. (2010). Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells. J. Exp. Med. 207, 2127-40.
147. Sato, A., Sunayama, J., Okada, M., Watanabe, E., Seino, S., Shibuya, K., et al. (2012). Glioma initiating cell elimination by metformin activation of FOXO3 via AMPK. Stem Cells Transl. Med. 1, 811-24.
148. Sauve, A. A., Wolberger, C., Schramm, V. L., and Boeke, J. D. (2006). The biochemistry of sirtuins. Annu. Rev. Biochem. 75, 435-65.
149. Schoenhals, M., Kassambara, A., De Vos, J., Hose, D., Moreaux, J., and Klein, B. (2009). Embryonic stem cell markers expression in cancers. Biochem. Biophys. Res. Commun. 383, 157-62.
150. Schreiber, V., Dantzer, F., Ame, J. C., and de Murcia, G. (2006). Poly(ADP-ribose): novel functions for an old molecule. Nat. Rev. Mol. Cell Biol. 7, 517-28.
151. Sen, N., Satija, Y. K, and Das, S. (2012). p53 and metabolism: old player in a new game. Transcription 3, 119-23.
152. Sen, N., Satija, Y. K., and Das, S. (2011). PGC-1a, a key modulator of p53, promotes cell survival upon metabolic stress. Mol. Cell 44, 621-34.
153. Shackleton, M., Quintana, E., Fearon, E. R., and Morrison, S. J. (2009). Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 138, 822-9.
154. Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., (2010). A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69-80.
155. Shu, J., Wu, C., Wu, Y., Li, Z., Shao, S., Zhao, W., et al. (2013). Induction of pluripotency in mouse somatic cells with lineage specifiers. Cell 153, 963-75.
156. Soda, Y., Marumoto, T., Friedmann-Morvinski, D., Soda, M., Liu, F., Michiue, H., et al. (2011). Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc. Natl. Acad. Sci. U S A 108, 4274-80.
157. Song, C. W., Lee, H., Dings, R. P., Williams, B., Powers, J., Santos, T. D., et al. (2012). Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci Rep. 2, 362.
158. Sonveaux, P., Ve´gran, F., Schroeder, T., Wergin, M. C., Verrax, J., Rabbani, Z. N., et al. (2008). De Saedeleer CJ, Kennedy KM, Diepart C, Jordan BF, Kelley MJ, Gallez B, Wahl ML, Feron O, Dewhirst MW. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J. Clin. Invest. 118, 3930-42.
159. Sotgia, F., Martinez-Outschoorn, U. E., Howell, A., Pestell, R.G., Pavlides, S., Lisanti, M. P. (2012). Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. Annu. Rev. Pathol. 7, 423-67.
160. Spike, B. T., and Wahl, G. M. (2011). p53, Stem Cells, and Reprogramming: Tumor Suppression beyond Guarding the Genome. Genes Cancer 2, 404-19.
161. Steinhauser, M. L., Bailey, A. P., Senyo, S. E., Guillermier, C., Perlstein, T. S., Gould, A. P., et al. (2012).Multi-isotope imaging mass spectrometry quantifies stem cell division and metabolism. Nature 481, 516-9.
162. Steinhauser, M. L., and Lechene, C. P. (2013). Quantitative imaging of subcellular metabolism with stable isotopes and multi-isotope imaging mass spectrometry. Semin. Cell Dev. Biol. 24, 661-7.
163. Sullivan, L. B., Martinez-Garcia, E., Nguyen, H., Mullen, A. R., Dufour, E., Sudarshan, S., et al. (2013). The proto-oncometabolite fumarate binds glutathione to amplify ROS-dependent signaling. Mol. Cell 51, 236-48.
164. Suva`, M. L., Riggi, N., and Bernstein, B. E. (2013). Epigenetic reprogramming in cancer. Science 339, 1567-70.
165. Tam, W. L., and Ng, H. H. (2014). Sox2: masterminding the root of cancer. Cancer Cell 26, 3-5.
166. Tapia, N., and Scho¨ler, H. R. (2010). p53 connects tumorigenesis and reprogramming to pluripotency. J. Exp. Med. 207, 2045-8.
167. Teperino, R., Schoonjans, K., and Auwerx, J. (2010). Histone methyl transferases and demethylases; can they link metabolism and transcription? Cell Metab 12, 321-7.
168. Terunuma, A., Putluri, N., Mishra, P., Mathe´, E. A., Dorsey, T. H., Yi, M., et al. (2014). MYC driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J. Clin. Invest. 124, 398-412.
169. Utikal, J., Polo, J. M., Stadtfeld, M., Maherali, N., Kulalert, W., Walsh, R. M., et al. (2009). Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature 460, 1145-8.
170. Vander Heiden, M. G., Cantley, L. C., and Thompson, C. B. (2009). Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 324, 1029-33.
171. Vander Heiden, M. G. (2013). Exploiting tumor metabolism: challenges for clinical translation. J. Clin. Invest. 123, 3648-51.
172. Vanner, R. J., Remke, M., Gallo, M., Selvadurai, H. J., Coutinho, F., Lee, L., et al. (2014). Quiescent sox2(+) cells drive hierarchical growth and relapse in sonic hedgehog subgroup medulloblastoma. Cancer Cell 26, 33-47.
173. Varlakhanova, N. V., and Knoepfler, P. S. (2009). Acting locally and globally: Myc's ever expanding roles on chromatin. Cancer Res 69, 7487-90.
174. Vazquez-Martin, A., Corominas-Faja, B., Cufi, S., Vellon, L., Oliveras-Ferraros, C., Menendez, O. J., et al. (2013). The mitochondrial H(+)-ATP synthase and the lipogenic switch: new core components of metabolic reprogramming in induced pluripotent stem (iPS) cells. Cell Cycle 12, 207-18.
175. Vazquez-Martin, A., Cufi, S., Corominas-Faja, B., Oliveras-Ferraros, C., Vellon, L., and Menendez, J. A. (2012a). Mitochondrial fusion by pharmacological manipulation impedes somatic cell reprogramming to pluripotency: new insight into the role of mitophagy in cell stemness. Aging (Albany NY) 4, 393-401.
176. Vazquez-Martin, A., Cufi, S., Lopez-Bonet, E., Corominas-Faja, B., Oliveras-Ferraros, C., Martin-Castillo, B., et al. (2012). Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency. Sci. Rep. 2, 964.
177. Vazquez-Martin, A., Lo´pez-Bonetc, E., Cufi´, S., Oliveras-Ferraros, C., Del Barco, S., Martin- Castillo, B., et al. (2011b). Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions. Drug Resist Updat 14, 212-23.
178. Vazquez-Martin, A., Oliveras-Ferraros, C., Cufi´, S., Del Barco, S., Martin-Castillo, B., and Menendez, J. A. (2010b). Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell Cycle 9, 3807-14.
179. Vazquez-Martin, A., Oliveras-Ferraros, C., Cufi´, S., Martin-Castillo, B., and Menendez, J. A. (2010a). Metformin and energy metabolism in breast cancer: from insulin physiology to tumour initiating stem cells. Curr. Mol. Med. 10, 674-91.
180. Vazquez-Martin, A., Oliveras-Ferraros, C., Del Barco, S., Martin-Castillo, B., and Menendez, J. A. (2011a). The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Res. Treat. 126, 355-64.
181. Vazquez-Martin, A., Vellon, L., Quiro´s, P. M., Cufi´, S., Ruiz de Galarreta, E., Oliveras-Ferraros, C., et al. (2012b). Activation of AMP-activated protein kinase (AMPK) provides a metabolic barrier to reprogramming somatic cells into stem cells. Cell Cycle 11, 974-89.
182. Vermeulen, L., de Sousa e Melo, F., Richel, D. J., and Medema, J. P. (2012). The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol. 13, e83-9.
183. Vicente-Dueñas, C., Hauer, J., Ruiz-Roca, L., Ingenhag, D., Rodri´guez-Meira, A., Auer, F., et al. (2014). Tumoral stem cell reprogramming as a driver of cancer: Theory, biological models, implications in cancer therapy. Semin. Cancer Biol. pii: S1044-579X(14)00025-X. doi: 10.1016/j.semcancer.2014.02.001
184. Visvader, J. E., and Lindeman, G. J. (2012). Cancer stem cells: current status and evolving complexities. Cell Stem Cell 10, 717-28.
185. Visvader, J. E. (2011). Cells of origin in cancer. Nature 469, 314-22
186. Waddington, C. H. (1957). The Strategy of the Genes: A Discussion of Some Aspects of Theoretical Biology (Allen & Unwin, London).
187. Wahlstro¨m, T., and Henriksson, M. A. (2014). Impact of MYC in regulation of tumor cell metabolism. Biochim. Biophys. Acta pii: S1874-9399(14)00192-8. doi: 10.1016/j.bbagrm.2014.07.004. [Epub ahead of print]
188. Wallace, D. C., and Fan, W. (2010). Energetics, epigenetics, mitochondrial genetics. Mitochondrion 10, 12-31.
189. Wang, S., Xia, P., Ye, B., Huang, G., Liu, J., and Fan, Z. (2013). Transient activation of autophagy via Sox2-mediated suppression of mTOR is an important early step in reprogramming to pluripotency. Cell Stem Cell 13, 617-25.
190. Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A, et al. (2010). The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17, 225-34.
191. Ward, P. S., and Thompson, C. B. (2012). Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 21, 297-308.
192. Wellen, K. E., Hatzivassiliou, G., Sachdeva, U. M., Bui, T. V., Cross, J. R., and Thompson, C. B. (2009). ATP-citrate lyase links cellular metabolism to histone acetylation. Science 324, 1076-80.
193. Wolf, A., Agnihotri, S., Munoz, D., and Guha, A. (2011). Developmental profile and regulation of the glycolytic enzyme hexokinase 2 in normal brain and glioblastoma multiforme. Neurobiol. Dis. 44, 84-91.
194. Wu, L. E., Gomes, A. P., and Sinclair, D. A. (2014). Geroncogenesis: metabolic changes during aging as a driver of tumorigenesis. Cancer Cell 25, 12-9.
195. Wu¨rth, R., Pattarozzi, A., Gatti, M., Bajetto, A., Corsaro, A., Parodi, A., et al. (2013). Metformin selectively affects human glioblastoma tumor-initiating cell viability: A role for metformin induced inhibition of Akt. Cell Cycle 12, 145-56.
196. Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S. H, et al. (2011). Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of a-ketoglutarate-dependent dioxygenases. Cancer Cell 19, 17-30.
197. Xu, X., Duan, S., Yi, F., Ocampo, A., Liu, G. H., and Izpisua Belmonte, J. C. (2013). Mitochondrial regulation in pluripotent stem cells. Cell Metab. 18, 325-32.
198. Yamanaka, S. (2009). Elite and stochastic models for induced pluripotent stem cell generation. Nature 460, 49-52.
199. Yang, M., Soga, T., Pollard, P. J., and Adam, J. (2012). The emerging role of fumarate as an oncometabolite. Front Oncol. 2, 85.
200. Yang, M., Soga, T., and Pollard, P. J. (2013). Oncometabolites: linking altered metabolism with cancer. J. Clin. Invest. 123, 3652-8.
201. Yang, X., Lin, X., Zhong, X., Kaur, S., Li, N., Liang, S., et al. (2010). Double-negative feedback loop between reprogramming factor LIN28 and microRNA let-7 regulates aldehyde dehydrogenase 1-positive cancer stem cells. Cancer Res. 70, 9463-72.
202. Ying, Q. L., Wray, J., Nichols, J., Batlle-Morera, L., Doble, B., Woodgett, J., et al. (2008). Theground state of embryonic stem cell self-renewal. Nature 453, 519-23.
203. Yuneva, M. O., Fan, T. W., Allen, T. D., Higashi, R. M., Ferraris, D. V., Tsukamoto, T., et al. (2012). The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab. 15, 157-70.
204. Zhang, J., Nuebel, E., Daley, G. Q., Koehler, C. M., and Teitell, M. A. (2012). Metabolic regulation in pluripotent stem cells during reprogramming and self-renewal. Cell Stem Cell 11, 589-95.
205. Zhang, Y., Li, W., Laurent, T., and Ding, S. (2012). Small molecules, big roles-the chemical manipulation of stem cell fate and somatic cell reprogramming. J. Cell Sci. 125, 5609-20.
206. Zhao, S., Xu, W., Jiang, W., Yu, W., Lin, Y., Zhang, T., et al. (2010). Regulation of cellular metabolism by protein lysine acetylation. Science 327, 1000-4.
207. Zhong, X., Li, N., Liang, S., Huang, Q., Coukos, G., and Zhang, L. (2010). Identification of microRNAs regulating reprogramming factor LIN28 in embryonic stem cells and cancer cells. J. Biol. Chem. 285, 41961-71.
208. Zhu, P., Davis, M., Blackwelder, A. J., Bachman, N., Liu, B., Edgerton, S., et al. (2014). Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models. Cancer Prev. Res. (Phila). 7, 199-210.